Q-omics provides the consensus-scored UBXN2A profile across patient tissues and cancer cell-line models. UBXN2A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBXN2A is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, UBXN2A RNA expression shows 20,858 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where UBXN2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBXN2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBXN2A survival associations across molecular data types. UBXN2A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBXN2A RNA expression–survival associations across cancer types. High UBXN2A expression shows unfavorable associations in ACC, LIHC, KICH, BLCA and LGG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBXN2A RNA expression.
This table summarizes UBXN2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for UBXN2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBXN2A shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, LIHC, LUSC and CHOL. The HNSC box plot shows higher UBXN2A RNA expression in tumor versus normal tissue (log2 FC = +0.655, t-test p < 0.001).
This table shows molecular features associated with UBXN2A in patient tissues and cancer cell lines. In patient samples, UBXN2A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBXN2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
